A Phase 4 interventional study of Denosumab and Alendronate Sodium in Nonalcoholic Fatty Liver and Osteoporosis, Postmenopausal, sponsored by Aristotle University Of Thessaloniki. Completed at 3 sites in Greece. Open to female participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by Aristotle University Of Thessaloniki · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Non-alcoholic Fatty Liver Disease with a site in Greece — 3 open to participants now, 6 under way, 2 of them phase 3. Non-alcoholic Fatty Liver Disease · Greece.
Among the 24 studies in Non-alcoholic Fatty Liver Disease with a site in Greece, this one is the 12th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2022, is one of 2 in phase 4, and was the 16th registered.
1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →3 of the 24 studies in Non-alcoholic Fatty Liver Disease with a site in Greece are open now. Recruiting first, the newest first:
Akero Therapeutics, Inc · Sites in Greece, United States, Argentina and 20 more countries
Ages 18–80
Attikon Hospital · Sites in Greece
Ages 18–75
Newcastle University · Sites in Greece, Belgium, Finland and 9 more countries
Ages 18–100
A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 40 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 100 across the 20 interventional studies, 264 across the 4 observational. Of the 17 that completed or were terminated, 5 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 24 have an industry lead sponsor. The 10 most frequent:
Aristotle University Of Thessaloniki is the lead sponsor of 282 studies on the registry; 55 are open to participants now.
Aristotle University Of Thessaloniki has 3 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
1 of the studies in Non-alcoholic Fatty Liver Disease with a site in Greece that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06523530Aristotle University Of ThessalonikiEffect of a GnRH Analog on Hepatic Steatosis | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Non-alcoholic Fatty Liver Disease with a site in Greece, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Nonalcoholic fatty liver disease (NAFLD) is a chronic, metabolic liver disease that is closely related to obesity, type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) in a bidirectional mode. NAFLD affects approximately 25% of the worldwide population. NAFLD refers to a phenotypic spectrum, including steatosis, inflammation and fibrosis, which can lead to cirrhosis and hepatocellular carcinoma in a minority of patients. However, despite its high prevalence, morbidity and mortality, as well as the extensive research in the field, there is not to-date a licensed medication specifically for NAFLD.
Emerging evidence supports a potential association between NAFLD and osteoporosis; the prevalence of osteoporosis is probably higher in patients with NAFLD and, vise versa, the prevalence of NAFLD may be higher in patients with osteoporosis. In this context, it has been proposed that certain medications for osteoporosis may also prove to be beneficial to NAFLD.
Denosumab, a human monoclonal IgG2 antibody against the receptor activator of nuclear factor kappa-B (NF-κB) ligand (RANKL), is currently an established treatment for osteoporosis and other metabolic bone diseases. The axis RANKL-receptor activator of nuclear factor NF-κB (RANK)-osteoprotegerin (OPG) has been demonstrated as a key regulator of bone metabolism and, when dysregulated, it contributes to the pathogenesis of osteoporosis and other metabolic bone diseases. Interestingly, experimental studies have shown that circulating and hepatic RANKL may be upregulated in mice with diet-induced NAFLD, rendering RANKL a potential contributor to the pathogenesis of NAFLD, and ideally, a promising pharmacological target.
On the other hand, bisphosphonates, another established, first-line treatment for osteoporosis, are expected to have no significant effect on hepatic metabolism in patients with NAFLD due to their pharmacokinetics and mechanism of action.
This is a prospective non-randomized study which aims to investigate the comparative effect of denosumab versus bisphosphonates on hepatic steatosis and fibrosis in women with postmenopausal osteoporosis and concomitant NAFLD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
35 postmenopausal women with low bone mineral density (BMD) and NAFLD will receive denosumab.
Drug: Denosumab
35 postmenopausal women with low bone mineral density (BMD) and NAFLD will receive alendronate.
Drug: Alendronate Sodium
60 mg (1ml) administered subcutaneously once every 6 months for 12 months (totally 2 injections). Patients will also be supplemented with calcium carbonate (1000 mg/d) and cholecalciferol (800 IU/day), according to the recent guidelines.
Also known as: Prolia
70 mg (1 tablet) administered per os once weekly for 12 months. Patients will also be supplemented with calcium carbonate (1000 mg/d) and cholecalciferol (800 IU/day), according to the recent guidelines.
Also known as: Fosamax
Hepatic steatosis: Ultrasound-Guided Attenuation Parameter (UGAP) measured on an ultrasound machine GE Logiq E10s.
1. Between-within group interactions in UGAP (baseline to endpoint) 2. Between groups difference in change in UGAP (baseline to endpoint) UGAP is a non-invasive index based on the attenuation quantification of the ultrasound beam through the hepatic parenchyma, thus used for hepatic steatosis quantification. Cut-off values of \> 0.53 dB/cm/MHz, \>0.60 dB/cm/MHz, and \>0.65 dB/cm/MHz have been proposed for the diagnosis of steatosis grade S1, S2, and S3, respectively.
Time frame: 12 months
Hepatic fibrosis: liver stiffness (LS) measured with 2D Shear Wave Elastography (2D SWE) on an ultrasound machine GE Logiq E10s.
1. Between-within group interactions in LS (baseline to endpoint) 2. Between groups difference in change in LS (baseline to endpoint) 2D SWE is a non-invasive tool measuring the hepatic parenchyma stiffness, thus indirectly suggesting fibrosis stage (F). Cut-offs values of \<8.27 kPa, 8.27-9.39 kPa, 9.40-11.88 kPa and \>11.88 kPa have been proposed for F0-F1, F2, F3, and F4, respectively.
Time frame: 12 months
Hepatic steatosis non-invasive index: Fatty Liver Index (FLI).
1. Between-within group interactions in FLI (baseline to endpoint) 2. Between groups difference in changes in FLI (baseline to endpoint) FLI is a non-invasive hepatic steatosis index, which is based on BMI, waist circumference, GGT and triglycerides. FLI ≥60 is associated with the presence of steatosis, while FLI \<30 rules out the presence of steatosis.
Time frame: 12 months
Hepatic steatosis non-invasive index: Hepatic Steatosis Index (HSI).
1. Between-within group interactions in HSI (baseline to endpoint) 2. Between groups difference in changes and HSI (baseline to endpoint) HSI is a non-invasive hepatic steatosis index, which is based on AST, ALT, BMI, gender and the presence or not of T2DM. HSI ≥36 is associated with the presence of steatosis, while HSI \<30 rules out the presence of steatosis.
Time frame: 12 months
Hepatic fibrosis non-invasive index: NAFLD fibrosis score (NFS).
1. Between-within group interactions in NFS (baseline to endpoint) 2. Between groups difference in changes in NFS (baseline to endpoint) NFS is a non-invasive hepatic fibrosis index, which is based on age, BMI, AST, ALT, platelets, albumin and the presence or not of T2DM. NFS \>0.675 is associated with high probability of advanced hepatic fibrosis (F3-F4), while NFS \<-1.455 is associated with low probability of advanced hepatic fibrosis (F3-F4).
Time frame: 12 months
Hepatic fibrosis non-invasive index: Fibrosis-4 index (FIB-4).
1. Between-within group interactions in FIB-4 (baseline to endpoint) 2. Between groups difference in changes in FIB-4 (baseline to endpoint) FIB-4 is a non-invasive hepatic fibrosis index, which is based on age, AST, ALT and platelets. FIB-4 ≥2.67 is associated with high probability of advanced hepatic fibrosis (F3-F4), while FIB-4 \<1.3 (when age \<65 years) or \<2.0 (when age ≥65 years) is associated with low probability of advanced hepatic fibrosis (F3-F4).
Time frame: 12 months
Hepatic fibrosis non-invasive index: AST-to-Platelet Ratio Index (APRI).
1. Between-within group interactions in APRI (baseline to endpoint) 2. Between groups difference in changes in APRI (baseline to endpoint) APRI is a non-invasive hepatic fibrosis index, which is based on AST, ALT and platelets. APRI ≥1 is associated with high probability of advanced hepatic fibrosis (F3-F4), while APRI \<0.5 is associated with low probability of advanced hepatic fibrosis (F3-F4).
Time frame: 12 months
Liver function tests: alanine aminotransferase (ALT).
Between-within group interactions in ALT (baseline to endpoint) The normal range for ALT is 4-36 U/L, but it may be different in different laboratories. Higher values may indicate hepatocellular injury.
Time frame: 12 months
Liver function tests: aspartate aminotransferase (AST)
Between-within group interactions in AST (baseline to endpoint) The normal range for AST is 8-33 U/L, but it may be different in different laboratories. Higher values may indicate hepatocellular injury.
Time frame: 12 months
Insulin resistance index: Homeostasis Model Assessment - Insulin Resistance (HOMA-IR)
Between-within group interactions in HOMA-IR (baseline to endpoint) HOMA-IR is calculated by the formula: fasting glucose (mg/dl) × insulin (mU/L)/405, and indicates the degree of insulin resistance; higher scores indicate greater insulin resistance. A HOMA-IR value ≥2.5 is indicative of insulin resistance.
Time frame: 12 months
Lipid profile: total cholesterol
Between-within group interactions in total cholesterol (baseline to endpoint) Total cholesterol levels \<200mg/dl are considered acceptable, 200-239 mg/dl are borderline high, and ≥240 mg/dl are considered high; however, these cut-offs differentiate according to other cardiovascular risk factors.
Time frame: 12 months
Lipid profile: triglycerides
Between-within group interactions in triglycerides (baseline to endpoint) Triglycerides levels \<150mg/dl are considered acceptable, 150-199 mg/dl are borderline high, and ≥200 mg/dl are considered high.
Time frame: 12 months
Lipid profile: low-density lipoprotein cholesterol (LDL-C)
Between-within group interactions in LDL-C (baseline to endpoint) LDL-C levels \<100mg/dl are considered optimal, 100-129 mg/dl are borderline high, and \>130 mg/dl are considered high; however, these cut-offs differentiate according to other cardiovascular risk factors.
Time frame: 12 months
Lipid profile: high-density lipoprotein cholesterol (HDL-C)
Between-within group interactions in HDL-C (baseline to endpoint) For women, the normal range for HDL-C is 50-90 mg/dl. Higher HDL-C are regarded as better.
Time frame: 12 months
Serum adipokines: leptin
Between-within group interactions in leptin (baseline to endpoint) For women, the normal range for leptin is 5-15 ng/ml, but it may be different for different ELISA kits.
Time frame: 12 months
Serum adipokines: adiponectin
Between-within group interactions in adiponectin (baseline to endpoint) The normal range for adiponectin is 5-30 μg/ml, but it may be different for different ELISA kits.
Time frame: 12 months
Plan to share: Yes — There is a plan to make IPD and related data dictionaries available
Supporting information: Study protocol, Statistical analysis plan
Time frame: 12 months after the publication of the study.
Access criteria: Yet unknown
Ran from Dec 2022 to primary completion in Jul 2026, 42 months.
Of 41 non-industry phase 4 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 46. This study's 42 months is above that.
Counting every sponsor, half of 44 studies reached it within 25 months; a quarter within 13 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab
Non-alcoholic Fatty Liver Disease →
Aristotle University Of Thessaloniki →